白介素-11在难治性特发性血小板减少性紫癜中的临床应用  

Clinical application of interleukin-11 on refractory idiopathic thrombocytopenic purpura

作　　者：孙川 李倩 

机构地区：[1]海南省农垦总医院血液科,海南海口570311

出　　处：《现代预防医学》2012年第22期6031-6032,6032,共2页Modern Preventive Medicine

摘　　要：目的检测难治性ITP患者内源性血清白介素-11(IL-11)的分泌水平。观察重组人白介素-11单药治疗难治性特发性血小板减少性紫癜(ITP)的临床效果。方法选血小板在2万以下的21例难治性ITP患者,应用ELISA法测定患者治疗前血清IL-11水平,以25例体检健康人为正常对照,比较治疗前内源性IL-11的分泌水平较正常人是否升高。用重组人IL-11单药治疗以上21例患者共14d,用法:50μg/kg,每天1次皮下注射,比较用药前后血小板计数是否存在差异。结果治疗前21例患者血清IL-11水平(246.0±133.5)pg/ml明显高于正常对照组(46.2±14.2)pg/ml(P﹤0.01)。21例患者用药前血小板计数平均值为(14.0±3.4)×109/L,用药后平均值为(58.9±35.1)×109/L,治疗后的血小板较治疗前显著升高(P﹤0.01)。治疗后2个月血小板平均值为(46.5±29.5)×109/L,比用药前高,但较d14下降。结论治疗前内源性IL-11水平分泌增高。IL-11能有效提高难治性ITP患者的血小板水平。OBJECTIVE To investigate the level of endogenous serum IL-11 before treatment in patients with refractory ITP,and observe the curative effect of recombinant human interleukin-11(rh IL-11)on refractory idiopathic thrombocytopenic purpura(ITP).METHODS The levels of IL-11 in twenty-one patients with refractory ITP were detected by enzyme linked immunosorbent assay(ELISA),25 healthy subjects were enrolled as controls.Twenty-one patients with refractory ITP were injected with 50μg/kg IL-11 subcutaneously,once a day,for 14 days,to compare platelet counts before and after treatment.RESULTS The mean level of endogenous IL-11 in patients was(246.0 ± 133.5)pg/ml,which was higher than the level in control group(46.2 ± 14.2)pg/ml.Before using rh IL-11,the mean platelet counts were(14.0 ± 3.4)×109/L.On the fourteenth day of treatment,the mean platelet counts was(58.9 ± 35.1)×109/L.On the two month of treatment the mean platlet counts was(46.5 ± 29.5)×109/L,which were significant differences.CONCLUSION The endogenous IL-11 elevated in patients with ITP.rh IL-11 can improve the platelet counts in patients with refractory ITP.

关 键 词：白介素- 难治性特发性血小板减少性紫癜 临床应用 

分 类 号：R554.6[医药卫生—血液循环系统疾病]